Compositions for modulating immune cell activity and methods for detection thereof
The invention relates to a new method for measuring cytotoxic activity of immune cells, and to methods and products for treating abnormal immune responses.
1 . A method for inhibiting an abnormal immune response comprising
administering to a subject in need thereof a gp120 molecule or functional equivalent thereof in an amount effective to inhibit an abnormal immune response.
2 . The method of claim 1 , wherein the abnormal immune response includes undesired infiltration of T cells.
3 . The method of claim 2 , wherein the gp120 molecule inhibits the undesired infiltration of T cells.
4 . The method of claim 1 , wherein the abnormal immune response is selected from the group consisting of autoimmune disease, immune hypersensitivity, allergy, asthma, graft-versus-host disease (GVHD), and inflammation.
5 . The method of claim 1 , wherein the abnormal immune response is reduced to a normal level.
6 . The method of claim 1 , wherein the gp120 molecule is a gp120 polypeptide or a fragment thereof.
7 . The method of claim 1 , wherein the gp120 molecule is a gp120 nucleic acid molecule.
8 . The method of claim 1 , wherein the gp120 molecule is a soluble gp120 molecule or a cell bound gp120 molecule.
9 . A method for enhancing migration of antigen-specific immune cells towards an antigen-expressing target comprising administering to a subject in need thereof an agent that inhibits gp120-mediated fugetaxis in an amount effective to enhance migration of antigen-specific immune cells towards an antigen-expressing target.
10 . The method of claim 9 , wherein the antigen-specific immune cells are antigen-specific cytotoxic T lymphocytes.
11 . The method of claim 9 , wherein the antigen-specific target is a cell free HIV virus or a cell-associated HIV virus.
12 . The method of claim 9 , wherein the agent is selected from the group consisting of anti-chemokine receptor antibody or a fragment thereof, a G-alpha-i inhibitor, a kinase inhibitor, and a cAMP agonist.
13 . The method of claim 12 , wherein the G-alpha-i inhibitor is a pertussis toxin or a functional equivalent thereof.
14 . The method of claim 12 , wherein the kinase inhibitor is selected from the group consisting of a phosphatidylinositol 3-kinase (PI3-K) inhibitor and a tyrosine kinase inhibitor.
15 . The method of claim 14 , wherein the phosphatidylinositol 3-kinase (PI3-K) inhibitor is wortmannin.
16 . The method of claim 14 , wherein the tyrosine kinase inhibitor is genistein or herbimycin.
17 . The method of claim 12 , wherein the cAMP agonist is a cyclic nucleotide.
18 . The method of claim 17 , wherein the cyclic nucleotide is 8-Br-cAMP or a functional equivalent thereof.
19 . The method of claim 9 , wherein the agent is administered systemically or in a sustained release vehicle.
20 . The method of claim 11 , further comprising administering an anti-HIV agent to the subject.
21 . The method of claim 11 , wherein the subject has an HIV infection.
22 . The method of claim 11 , wherein the subject is at risk of developing an HIV infection.
23 . The method of claim 22 , wherein the subject has been exposed to HIV.
24 . The method of claim 9 , wherein the antigen-specific immune cells with cytotoxic activity are cytotoxic CD8+ T lymphocytes, natural killer (NK) cells, neutrophils, cytotoxic CD4+ T lymphocytes, and macrophages.
25 . The method of claim 9 , wherein the anti-chemokine receptor antibody or a fragment thereof is an anti-CXCR4 antibody or a fragment thereof, or anti-CXCR5 antibody or a fragment thereof.
26 . The method of claim 9 , wherein the antigen-specific immune cell is an antigen-specific immune cell with cytotoxic activity.
27 . A method for measuring activity of immune cells with cytotoxic activity comprising
placing at least one effector cell and at least one target cell in a flat bottom chamber,
incubating the cells for a time sufficient to allow lysing of the at least one target cell by the at least one effector cell, and
determining a proportion of target cells lysed,
wherein the proportion of target cells lysed is measured using a non-fluorescent assay, and
wherein the effector cell is an immune cell with cytotoxic activity.
28 . The method of claim 27 , wherein the non-fluorescent assay is radioactivity release.
29 . The method of claim 27 , wherein the at least one effector cell and the at least one target cell are present in a pre-defined ratio.
30 . The method of claim 29 , wherein the pre-defined ratio is selected from the group consisting of 1000:1, 750:1, 500:1, 250:1, 100:1, 50:1, 10:1, 5:1 and 1:1.
31 . The method of claim 27 , further comprising comparing results of the assay to a standard curve.
32 . The method of claim 27 , wherein a total number of cells per flat bottom chamber is constant.
33 . The method of claim 27 , wherein the total number of cells per flat bottom chamber is selected from the group consisting of at least 10,000, at least 20,000, at least 25,000, at least 50,000, at least 75,000, at least 100,000, at least 125,000, at least 150,000, at least 175,000, and at least 200,000.
34 . The method of claim 27 , wherein the immune cell with cytotoxic activity is selected from the group of cells consisting of cytotoxic CD8+ T lymphocytes, natural killer (NK) cells, neutrophils, cytotoxic CD4+ T lymphocytes, and macrophages.
35 . The method of claim 27 , wherein the immune cell with cytotoxic activity is a cytotoxic CD8+ T lymphocyte.
36 . A method for measuring activity of immune cells with cytotoxic activity comprising
placing at least one effector cell and at least one target cell in a flat bottom chamber,
incubating the cells for a time sufficient to allow lysing of the at least one target cell by the at least one effector cell, and
determining a proportion of target cells lysed,
wherein the proportion of target cells lysed is measured using a flow cytometer or a radioactivity counter, and
wherein the effector cell is an immune cell with cytotoxic activity.
37 . The method of claim 36 , wherein the radioactivity counter is used to measure radioactive chromium release.
38 . The method of claim 36 , wherein the flow cytometer is used to measure propidium iodide, 7-AAD or fluorogenic caspase substrate.
38 . The method of claim 36 , wherein the at least one effector cell and the at least one target cell are present in a pre-defined ratio.
40 . The method of claim 38 , wherein the pre-defined ratio is selected from the group consisting of 1000:1, 750:1, 500:1, 250:1, 100:1, 50:1, 10:1, 5:1 and 1:1.
41 . The method of claim 36 , further comprising comparing results of the assay to a standard curve.
42 . The method of claim 36 , wherein a total number of cells per flat bottom chamber is constant.
43 . The method of claim 36 , wherein the total number of cells per flat bottom chamber is selected from the group consisting of at least 10,000, at least 20,000, at least 25,000, at least 50,000, at least 75,000, at least 100,000, at least 125,000, at least 150,000, at least 175,000, and at least 200,000.
44 . The method of claim 36 , wherein the immune cell with cytotoxic activity is selected from the group of cells consisting of cytotoxic CD8+ T lymphocytes, natural killer (NK) cells, neutrophils, cytotoxic CD4+ T lymphocytes, and macrophages.
45 . The method of claim 36 , wherein the immune cell with cytotoxic activity is a cytotoxic CD8+ T lymphocyte.
46 . A method for measuring activity of immune cells with cytotoxic activity comprising
placing at least one effector cell and at least one target cell in a flat bottom chamber,
incubating the cells for a time sufficient to allow lysing of the at least one target cell by the at least one effector cell,
determining a proportion of target cells lysed, and
comparing the proportion of target cells lysed to a standard curve,
wherein the effector cell is an immune cell with cytotoxic activity.
47 . The method of claim 46 , wherein the proportion of target cells lysed is measured by fluorescence or radioactivity release.
48 . The method of claim 46 , wherein the proportion of target cells lysed is measured using a flow cytometer or a radioactivity counter.
49 . The method of claim 48 , wherein the radioactivity counter is used to measure radioactive chromium release.
50 . The method of claim 46 , wherein the flow cytometer is used to measure propidium iodide, 7-AAD or fluorogenic caspase substrate.
51 . The method of claim 46 , wherein the at least one effector cell and the at least one target cell are present in a pre-defined ratio.
52 . The method of claim 51 , wherein the pre-defined ratio is selected from the group consisting of 1000:1, 750:1, 500:1, 250:1, 100:1, 50:1, 10:1, 5:1 and 1:1.
53 . The method of claim 46 , wherein the total number of cells per flat bottom chamber is constant.
54 . The method of claim 46 , wherein the total number of cells per flat bottom chamber is selected from the group consisting of at least 10,000, at least 20,000, at least 25,000, at least 50,000, at least 75,000, at least 100,000, at least 125,000, at least 150,000, at least 175,000, and at least 200,000.
55 . The method of claim 46 , wherein the immune cell with cytotoxic activity is selected from the group of cells consisting of cytotoxic CD8+ T lymphocytes, natural killer (NK) cells, neutrophils, cytotoxic CD4+ T lymphocytes, and macrophages.
56 . The method of claim 46 , wherein the immune cell with cytotoxic activity is a cytotoxic CD8+ T lymphocyte.